Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPENDAGE: Aspirin vs Aspirin + Clopidogrel After Left Atrial Appendage Closure
NCT04796714Phase 4Recruiting
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Oct 2022
- Primary completion
- May 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of clopidogrel in Atrial fibrillation (AFib) (2 arms), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Change from baseline of ischaemic lesions number on brain MRI scans at 3 months. Started Oct 2022; status: recruiting.
02
Drugs
clopidogrel
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT04796714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04796714.